NCT02520102View on ClinicalTrials.gov

Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2017

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Acute Myeloid Leukemia NOS
Interventions
DRUG

sargramostim GZ402664

"Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous"

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY